IP Library Granted Patent US 10,561,460
Granted Patent B2
US 10,561,460 · App. 15/654,062 · Granted Feb 18, 2020

Neuromodulation systems and methods for treatment of sexual dysfunction

Inventors: Andrew Wu (Los Altos Hills, CA); Benjamin J. Clark (Redwood City, CA); Denise Zarins (Saratoga, CA); Erik Thai (San Jose, CA)
Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
A61B18/1492A61B18/1206A61M25/0141A61B18/02A61B18/18A61B18/24A61B90/39A61B2017/003A61B2018/00172A61B2018/00404A61B2018/00434A61B2018/00511A61B2018/00577A61B2018/00648A61B2018/00791A61B2018/00875A61N2007/003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,561,460
App. No.
15/654,062
Granted
Feb 18, 2020
Kind
B2
Abstract

Apparatus, systems, and methods for achieving thermally-induced renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a thermal element to a renal artery via an intravascular path. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers.

Claims (30)

1. A method for treating a human patient diagnosed with erectile dysfunction or premature ejaculation, the method comprising:

advancing a neuromodulation assembly along an intravascular path to a position within a target blood vessel of a human patient, wherein the neuromodulation assembly is at a distal portion of a treatment device, and wherein the position within the target blood vessel is proximate to neural fibers innervating penile tissue of the human patient;

at least partially disrupting function of the neural fibers innervating the penile tissue by applying thermal energy to the neural fibers via the neuromodulation assembly; and

retracting the neuromodulation assembly along the intravascular path to remove the neuromodulation assembly from the patient after treatment,

wherein at least partial disruption of the function of the neural fibers innervating the penile tissue therapeutically treats the diagnosed erectile dysfunction or premature ejaculation.

2. The method of claim 1 wherein the neuromodulation assembly is introduced percutaneously.

3. The method of claim 1 wherein the patient is diagnosed with premature ejaculation, and wherein at least partial disruption of the function of the neural fibers decreases a frequency of premature ejaculation in the patient.

4. The method of claim 1 wherein the patient is diagnosed with erectile dysfunction, and wherein at least partial disruption of the function of the neural fibers increases a frequency of penile erections in the patient.

5. The method of claim 1 wherein the target blood vessel is the inferior mesenteric artery of the patient.

6. A method for treating erectile dysfunction in a human patient, the method comprising:

transluminally advancing a catheter along an intravascular path to position an energy delivery element of the catheter within a target blood vessel of the patient and adjacent to neural fibers that innervate penile tissue of the patient;

at least partially ablating the neural fibers innervating the penile tissue of the patient via the energy delivery element; and

retracting the catheter along the intravascular path to remove the neuromodulation assembly from the patient after treatment,

wherein at least partially ablating the neural fibers results in a therapeutically beneficial reduction in one or more physiological conditions associated with erectile dysfunction of the patient.

7. The method of claim 6 wherein the reduction in one or more physiological conditions associated with erectile dysfunction includes a reduction in the number of instances of impotence in the patient.

8. The method of claim 6 wherein the target blood vessel the inferior mesenteric artery of the patient.

9. A method of treating a human patient diagnosed with erectile dysfunction, the method comprising:

intravascularly advancing a neuromodulation assembly along an intravascular path to a position within a target blood vessel of the patient that is adjacent to a target sympathetic nerve of the patient;

reducing sympathetic neural activity in the patient by delivering energy to the target sympathetic nerve via the neuromodulation assembly; and

retracting the neuromodulation assembly along the intravascular path to remove the neuromodulation assembly from the patient after treatment,

wherein reducing sympathetic neural activity therapeutically treats the diagnosed erectile dysfunction.

10. The method of claim 9 wherein reducing sympathetic neural activity in the patient increases a frequency of penile erections in the patient.

11. The method of claim 9 wherein reducing sympathetic neural activity in the patient by delivering energy to the target sympathetic nerve comprises at least partially inhibiting efferent neural activity.

12. The method of claim 9 wherein reducing sympathetic neural activity in the patient by delivering energy to the target sympathetic nerve comprises selectively neuromodulating efferent penile nerves in the patient compared to afferent penile nerves in the patient.

13. The method of claim 9 wherein reducing sympathetic neural activity in the patient by delivering energy to the target sympathetic nerve comprises at least partially inhibiting afferent neural activity.

14. The method of claim 9 wherein reducing sympathetic neural activity in the patient by delivering energy to the target sympathetic nerve comprises thermally modulating the target sympathetic nerve of the patient via an intravascularly positioned catheter carrying the neuromodulation assembly.

15. The method of claim 14 wherein thermally modulating the target sympathetic nerve comprises at least partially ablating the target sympathetic nerve via the neuromodulation assembly.

16. The method of claim 14 wherein thermally modulating the target sympathetic nerve comprises cryotherapeutically cooling the target sympathetic nerve.

17. The method of claim 14 wherein thermally modulating the target sympathetic nerve comprises heating the target sympathetic nerve.

18. The method of claim 9 wherein the target blood vessel is the inferior mesenteric artery of the patient.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2017
From: WU, ANDREW; CLARK, BENJAMIN J.; ZARINS, DENISE; THAI, ERIK
To: ARDIAN, INC.
Reel/Frame 043045/0951 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2017
From: MEDTRONIC ARDIAN LLC
To: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
Reel/Frame 043046/0037 →
CHANGE OF NAME Recorded Jul 19, 2017
From: ARDIAN, INC.
To: MEDTRONIC ARDIAN LLC
Reel/Frame 043251/0989 →
Priority Claims (3)
EP 09167937 · Aug 14, 2009 · regional
EP 09168202 · Aug 14, 2009 · regional
EP 09168204 · Aug 14, 2009 · regional
Continuity (7)
Continuation 14636459 · Mar 3, 2015
Continuation 14284474 · May 22, 2014
Continuation 12910631 · Oct 22, 2010
Continuation 12545648 · Aug 21, 2009
Continuation In Part 12495691 · Jun 30, 2009
Provisional Application 61142128 · Dec 31, 2008
Related Publication 20170319272A1 · Nov 9, 2017